Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey

Basit Öğe Kaydı
dc.WoS.categoriesOncologyen_US
dc.authorid0000-0003-0917-2098en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorDuymaz, Tomris
dc.date.accessioned2023-09-26T06:54:52Z
dc.date.available2023-09-26T06:54:52Z
dc.date.issued2023-06-28
dc.description.abstractBackground: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patients treated with adjuvant therapy based on tumor board decisions. Patients and methods: Estrogen-positive HER-2 negative early-stage breast cancer patients (pT1-2 N0, N1mic) with known ODx-RS, operated on between 2010 and 2014, were included in this study. The primary aim was to evaluate 5-year disease-free survival (DFS) rates according to ODX-RS. Results: A total of 203 eligible patients were included in the study, with a median age of 48 (range 26-75) and median follow-up of 84 (range 23-138) months. ROC curve analysis for all patients revealed a recurrence cut-off age of 45 years, prompting evaluation by grouping patients as <= 45 years vs. >45 years. No significant difference in five-year DFS rates was observed between the endocrine-only (ET) and chemo-endocrine (CE) groups. However, among the ET group, DFS was higher in patients over 45 years compared to those aged <= 45 years. When stratifying by ODx-RS as 0-17 and >= 18, DFS was significantly higher in the former group within the ET group. However, such differences were not seen in the CE group. In the ET group, an ODx-RS >= 18 and menopausal status were identified as independent factors affecting survival, with only an ODx-RS >= 18 impacting DFS in patients aged <= 45 years. The ROC curve analysis for this subgroup found the ODx-RS cut-off to be 18. Conclusion: This first multicenter Oncotype Dx survival analysis in Turkey demonstrates the importance of Oncotype Dx recurrence score and age in determining treatment strategies for early-stage breast cancer patients. As a different aproach to the literature, our findings suggest that the addition of chemotherapy to endocrine therapy in young patients (<= 45 years) with Oncotype Dx recurrence scores of >= 18 improves DFS.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.3389/fonc.2023.1151733
dc.identifier.issn2234-943X
dc.identifier.pmid37448522en_US
dc.identifier.scopus2-s2.0-85164956724en_US
dc.identifier.urihttps://hdl.handle.net/11411/5210
dc.identifier.urihttps://doi.org/10.3389/fonc.2023.1151733
dc.identifier.wosWOS:001027956800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors10+en_US
dc.publisherFRONTIERS MEDIA SAen_US
dc.relation.ispartofFRONTIERS IN ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectclinicopathologic characteristicsen_US
dc.subjectearly-stage breast canceren_US
dc.subjectlymph node-negativeen_US
dc.subjectOncotype DX (R)en_US
dc.subjectrecurrence scoreen_US
dc.subject21 genesen_US
dc.titleSurvival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
dc.typeArticle
dc.volume13en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2023WosDuymaz.pdf
Boyut:
835.46 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
Web of Science Indexed Publications